Suppr超能文献

中国肝微粒体中细胞色素 P450 酶的代谢能力与白种人肝微粒体中的比较。

Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.

机构信息

Shanghai Institute of Materia, Chinese Academy of Sciences, Shanghai, China.

出版信息

Br J Clin Pharmacol. 2012 Feb;73(2):268-84. doi: 10.1111/j.1365-2125.2011.04076.x.

Abstract

AIM

The most common causes of variability in drug response include differences in drug metabolism, especially when the hepatic cytochrome P450 (CYP) enzymes are involved. The current study was conducted to assess the differences in CYP activities in human liver microsomes (HLM) of Chinese or Caucasian origin.

METHODS

The metabolic capabilities of CYP enzymes in 30 Chinese liver microsomal samples were compared with those of 30 Caucasian samples utilizing enzyme kinetics. Phenacetin O-deethylation, coumarin 7-hydroxylation, bupropion hydroxylation, amodiaquine N-desethylation, diclofenac 4'-hydroxylation (S)-mephenytoin 4'-hydroxylation, dextromethorphan O-demethylation, chlorzoxazone 6-hydroxylation and midazolam 1'-hydroxylation/testosterone 6β-hydroxylation were used as probes for activities of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A, respectively. Mann-Whitney U test was used to assess the differences.

RESULTS

The samples of the two ethnic groups were not significantly different in cytochrome-b(5) concentrations but were significantly different in total CYP concentrations and NADPH-P450 reductase activity (P < 0.05). Significant ethnic differences in intrinsic clearance were observed for CYP1A2, CYP2C9, CYP2C19 and CYP2E1; the median values of the Chinese group were 54, 58, 26, and 35% of the corresponding values of the Caucasian group, respectively. These differences were associated with differences in Michaelis constant or maximum velocity. Despite negligible difference in intrinsic clearance, the Michaelis constant of CYP2B6 appeared to have a significant ethnic difference. No ethnic difference was observed for CYP2A6, CYP2C8, CYP2D6 and CYP3A.

CONCLUSIONS

These data extend our knowledge on the ethnic differences in CYP enzymes and will have implications for drug discovery and drug therapy for patients from different ethnic origins.

摘要

目的

药物反应变异性的最常见原因包括药物代谢的差异,尤其是当涉及到肝细胞色素 P450(CYP)酶时。本研究旨在评估中西方人群肝微粒体(HLM)中 CYP 活性的差异。

方法

利用酶动力学比较 30 个中国肝微粒体样本和 30 个白种人肝微粒体样本中 CYP 酶的代谢能力。利用酶动力学比较 30 个中国肝微粒体样本和 30 个白种人肝微粒体样本中 CYP 酶的代谢能力。以苯乙酮 O-去乙基化、香豆素 7-羟化、丁丙诺啡羟化、阿莫地喹 N-去乙基化、双氯芬酸 4'-羟化(S)-美芬妥因 4'-羟化、右美沙芬 O-去甲基化、氯唑沙宗 6-羟化和咪达唑仑 1'-羟化/睾酮 6β-羟化分别作为 CYP1A2、CYP2A6、CYP2B6、CYP2C8、CYP2C9、CYP2C19、CYP2D6、CYP2E1 和 CYP3A 的活性探针。采用曼-惠特尼 U 检验评估差异。

结果

两组样本在细胞色素 b5 浓度上无显著差异,但在总 CYP 浓度和 NADPH-P450 还原酶活性上有显著差异(P<0.05)。CYP1A2、CYP2C9、CYP2C19 和 CYP2E1 的内在清除率存在显著的种族差异;中国组的中位数分别为白种人组相应值的 54%、58%、26%和 35%。这些差异与米氏常数或最大速度有关。尽管内在清除率差异很小,但 CYP2B6 的米氏常数似乎存在显著的种族差异。CYP2A6、CYP2C8、CYP2D6 和 CYP3A 则没有种族差异。

结论

这些数据扩展了我们对 CYP 酶种族差异的认识,将对不同种族来源的患者的药物发现和药物治疗产生影响。

相似文献

2
Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity.
Arch Biochem Biophys. 1996 Jul 15;331(2):145-69. doi: 10.1006/abbi.1996.0294.
4
6
In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates.
J Pharm Pharmacol. 2012 Oct;64(10):1445-51. doi: 10.1111/j.2042-7158.2012.01516.x. Epub 2012 May 2.
7
Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat.
Biochem Pharmacol. 2002 Mar 1;63(5):889-96. doi: 10.1016/s0006-2952(01)00843-7.
9
The inhibitory effect of tannic acid on cytochrome P450 enzymes and NADPH-CYP reductase in rat and human liver microsomes.
Food Chem Toxicol. 2008 Feb;46(2):645-53. doi: 10.1016/j.fct.2007.09.073. Epub 2007 Sep 15.

引用本文的文献

2
Metabolic Activation of 2-Methylfuran to Acetylacrolein and Its Reactivity toward Cellular Proteins.
Chem Res Toxicol. 2024 Nov 18;37(11):1807-1820. doi: 10.1021/acs.chemrestox.4c00083. Epub 2024 Sep 6.
5
Reply to "A better interpretation of data regarding the opioid switching to methadone".
BMC Palliat Care. 2023 Jun 7;22(1):66. doi: 10.1186/s12904-023-01162-z.
6
Current Research Trends in the Application of In Vitro Three-Dimensional Models of Liver Cells.
Pharmaceutics. 2022 Dec 24;15(1):54. doi: 10.3390/pharmaceutics15010054.
7
8
Effective low-dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon in young infants.
Br J Clin Pharmacol. 2022 Jun;88(6):2769-2781. doi: 10.1111/bcp.15202. Epub 2022 Jan 18.
9
CYP1A2 polymorphism may contribute to agomelatine-induced acute liver injury: Case report and review of the literature.
Medicine (Baltimore). 2021 Nov 12;100(45):e27736. doi: 10.1097/MD.0000000000027736.
10
A Novel Statin Compound from Monacolin J Produced Using CYP102A1-Catalyzed Regioselective C-Hydroxylation.
Pharmaceuticals (Basel). 2021 Sep 26;14(10):981. doi: 10.3390/ph14100981.

本文引用的文献

1
The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations.
Per Med. 2004 Dec;1(1):63-84. doi: 10.1517/17410541.1.1.63.
3
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.
Br J Clin Pharmacol. 2010 Mar;69(3):222-30. doi: 10.1111/j.1365-2125.2009.03578.x.
4
CYP2E1 and risk of chemically mediated cancers.
Expert Opin Drug Metab Toxicol. 2010 Mar;6(3):307-19. doi: 10.1517/17425250903540238.
5
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
Pharmacogenomics. 2009 Sep;10(9):1489-510. doi: 10.2217/pgs.09.82.
6
Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase.
Nat Protoc. 2009;4(9):1245-51. doi: 10.1038/nprot.2009.121. Epub 2009 Aug 6.
10
P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity.
Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):439-52. doi: 10.1517/17425255.4.4.439.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验